ITCI Intra-Cellular Therapies Inc

Price (delayed)

$36.135

Market cap

$2.93B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.15

Enterprise value

$2.83B

Highlights
The revenue has soared by 65% from the previous quarter
The gross profit has soared by 64% from the previous quarter
The equity has increased by 42% year-on-year but it has declined by 7% since the previous quarter
The debt has grown by 23% year-on-year but it has declined by 3.2% since the previous quarter
The net income is down by 45% YoY and by 2.3% from the previous quarter
ITCI's gross margin is down by 2.8% YoY

Key stats

What are the main financial stats of ITCI
Market
Shares outstanding
81.2M
Market cap
$2.93B
Enterprise value
$2.83B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.78
Price to sales (P/S)
77.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.28
Earnings
Revenue
$37.61M
EBIT
-$232.32M
EBITDA
-$231.81M
Free cash flow
-$226.86M
Per share
EPS
-$3.15
Free cash flow per share
-$2.8
Book value per share
$7.57
Revenue per share
$0.46
TBVPS
$8.33
Balance sheet
Total assets
$674.49M
Total liabilities
$62.34M
Debt
$28.21M
Equity
$612.15M
Working capital
$609.4M
Liquidity
Debt to equity
0.05
Current ratio
16.35
Quick ratio
15.79
Net debt/EBITDA
0.45
Margins
EBITDA margin
-616.4%
Gross margin
91.3%
Net margin
-617.8%
Operating margin
-625.8%
Efficiency
Return on assets
-35.7%
Return on equity
-39.4%
Return on invested capital
-48%
Return on capital employed
-36.6%
Return on sales
-617.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ITCI stock price

How has the Intra-Cellular Therapies stock price performed over time
Intraday
-2.39%
1 week
-0.73%
1 month
-16.53%
1 year
69.17%
YTD
13.63%
QTD
-11.48%

Financial performance

How have Intra-Cellular Therapies's revenue and profit performed over time
Revenue
$37.61M
Gross profit
$34.33M
Operating income
-$235.36M
Net income
-$232.34M
Gross margin
91.3%
Net margin
-617.8%
The net margin has surged by 96% year-on-year and by 38% since the previous quarter
The operating margin has soared by 96% YoY and by 38% from the previous quarter
The revenue has soared by 65% from the previous quarter
The gross profit has soared by 64% from the previous quarter

Growth

What is Intra-Cellular Therapies's growth rate over time

Valuation

What is Intra-Cellular Therapies stock price valuation
P/E
N/A
P/B
4.78
P/S
77.78
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.28
The EPS has contracted by 13% YoY but it has grown by 2.5% from the previous quarter
ITCI's P/B is 65% above its 5-year quarterly average of 2.9 and 26% above its last 4 quarters average of 3.8
The equity has increased by 42% year-on-year but it has declined by 7% since the previous quarter
The revenue has soared by 65% from the previous quarter
The stock's price to sales (P/S) is 65% less than its last 4 quarters average of 225.3

Efficiency

How efficient is Intra-Cellular Therapies business performance
The ROS has soared by 96% YoY and by 38% from the previous quarter
ITCI's return on invested capital is up by 40% year-on-year and by 10% since the previous quarter
The ROE has grown by 32% YoY and by 6% from the previous quarter
Intra-Cellular Therapies's ROA has increased by 26% YoY and by 5% from the previous quarter

Dividends

What is ITCI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ITCI.

Financial health

How did Intra-Cellular Therapies financials performed over time
Intra-Cellular Therapies's total assets has increased by 40% YoY but it has decreased by 6% from the previous quarter
The total liabilities has increased by 23% YoY and by 3.1% from the previous quarter
The debt is 95% smaller than the equity
The equity has increased by 42% year-on-year but it has declined by 7% since the previous quarter
ITCI's debt to equity is up by 25% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.